Every material Form 8-K West Pharmaceutical Services filed with the SEC in 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
West Pharmaceutical Services reported third-quarter 2026 net sales of $874.5 million and diluted earnings per share of $3.02, reflecting growth compared to the prior-year period. Driven by strong execution in its Proprietary Products segment, the company raised its full-year net sales and adjusted-diluted EPS guidance ranges.
Q3 2026 net sales reached $874.5 million, up 8.7% year-over-year, with diluted EPS of $3.02.
Full-year 2026 net sales guidance was increased to a range of $3.41 billion to $3.42 billion.
Full-year 2026 adjusted-diluted EPS guidance was raised to a range of $9.38 to $9.48.
The company repurchased $231 million of stock in the third quarter, bringing year-to-date repurchases to $685 million.
On October 26, 2026, West Pharmaceutical Services entered a new credit agreement with Bank of America as administrative agent. It includes a $750 million revolving facility and a $200 million term loan advanced on the effective date, and the company used the borrowings to repay $130.0 million outstanding under its 2019 credit agreement, which it terminated with no early termination penalties. The filing reports no change to earnings or guidance, but it sets new debt terms, including a maximum net leverage ratio of 3.50 to 1.0.
New credit agreement provides a $750 million revolving facility and a $200 million term loan, with a five-year term from October 26, 2026.
$130.0 million outstanding under the 2019 credit agreement was repaid in full on October 26, 2026, with no early termination penalties.
Borrowings are unsecured; the net leverage covenant caps the ratio at 3.50 to 1.0, or 4.00 to 1.0 during material acquisition periods.
Term loan quarterly amortization starts March 31, 2028, at $1.25 million to $2.5 million per quarter, with the balance due at maturity.
West Pharmaceutical Services reported second-quarter 2026 net sales of $872.3 million, up 13.8%, and diluted EPS of $2.15, up 18.1%. The company raised its full-year 2026 net sales guidance to $3.345 billion to $3.380 billion and its adjusted-diluted EPS guidance to $8.85 to $9.05, which suggests stronger expected profitability for shareholders.
Q2 2026 net sales of $872.3 million rose 13.8%; organic growth was 12.7%, led by HVP Components at $424.1 million, up 19.4%.
Q2 diluted EPS was $2.15, up from $1.82; adjusted-diluted EPS was $2.37, up 28.8%.
Full-year 2026 adjusted-diluted EPS guidance rose to $8.85 to $9.05 from $8.40 to $8.75.
Q3 2026 adjusted-diluted EPS guidance is $2.14 to $2.24, and Q3 net sales are expected at $820 million to $835 million.
West Pharmaceutical Services entered into an amended and restated crosslicense agreement and two distributorship agreements with Daikyo Seiko, effective July 14, 2026, which the company says are substantially similar to the 2017 agreements as amended in 2018 and 2019. West holds a 49% ownership interest in Daikyo, and the filing describes the agreements as sharing know-how and granting licenses for pharmaceutical packaging and delivery components, with each agreement running 10 years.
Agreements are effective July 14, 2026 and each has a 10-year term
West is the exclusive distributor of Daikyo products outside Japan, subject to limited exceptions
Daikyo is a non-exclusive distributor of West products in Japan
Full agreement texts will be filed as redacted exhibits to the 10-Q for the quarter ending September 30, 2026
West Pharmaceutical Services said its Board appointed Michel Lagarde, formerly Executive Vice President and Chief Operating Officer at Thermo Fisher Scientific, as President and Chief Executive Officer effective August 31, 2026, replacing Eric M. Green, who is retiring. Lead Independent Director Robert F. Friel will become Board Chair on the same date, and Mr. Lagarde will join the Board as a director.
Mr. Lagarde's annual base salary is $1,175,000, with a target annual incentive of 125% of salary, or $1,468,750.
His 2026 long-term incentive award has a total grant value of $8,611,111, and a one-time sign-on grant has a total grant date value of $6,875,000.
Matching inducement grants are based on his personal stock purchases between May 31, 2026 and the start date, capped at $2,500,000.
Mr. Green's transition was first disclosed on March 9, 2026, when he told the Board on March 6, 2026 of his intent to retire.
West Pharmaceutical Services said on May 7, 2026 that it had determined it experienced a material cyberattack, in which certain data was exfiltrated and certain systems were encrypted. The company took systems offline globally after detecting an intrusion on May 4, 2026, and says the incident has temporarily disrupted its business operations worldwide; the full restoration timeline has not been finalized and the financial impact has not been determined.
Intrusion first detected May 4, 2026; the company determined on May 7, 2026 that it was a material cyberattack
Certain data was exfiltrated and certain systems were encrypted; the investigation into the scope, including the data affected, is ongoing
Core enterprise systems have been restored, and shipping, receiving and manufacturing have restarted at some sites, with remaining sites in process
Impact on financial condition and results of operations has not been determined; law enforcement was notified and Palo Alto Networks' Unit 42 was engaged
West Pharmaceutical reported first-quarter 2026 net sales of $844.9 million, up 21.0% from a year earlier, and diluted EPS of $1.92, up 56.1%. The company raised its full-year 2026 net sales guidance to $3.295 billion to $3.350 billion and its adjusted-diluted EPS guidance to $8.40 to $8.75, and it repurchased $297.6 million of its shares during the quarter.
First-quarter net sales were $844.9 million, up 21.0% reported and 15.3% organic, versus $698.0 million a year earlier.
Diluted EPS was $1.92, up from $1.23; adjusted-diluted EPS was $2.13, up 46.9%.
Full-year 2026 adjusted-diluted EPS guidance rose to $8.40 to $8.75, from $7.85 to $8.20.
Cash and cash equivalents fell to $521.4 million at March 31, 2026, from $791.3 million at December 31, 2025, after share repurchases.
CEO Eric Green told the Board on March 6, 2026 that he intends to retire as President, Chief Executive Officer and Chair once a successor is hired. The Board is engaging an executive recruiting firm and expects the transition in the second half of 2026. The company also reaffirmed its 2026 financial guidance from its February 12, 2026 earnings release, which matters to shareholders because it is a leadership change at the top of the company with no change to the outlook.
Eric M. Green informed the Board on March 6, 2026 of his intent to retire as President, CEO and Chair of the Board once his successor is hired.
The Board expects the transition to occur in the second half of 2026 and is engaging a leading executive recruiting firm.
The company reaffirmed the 2026 financial guidance provided in its February 12, 2026 earnings release.
Green has been CEO since April 2015 and Chair since May 2022; the company says sales more than doubled and total shareholder return was approximately 350% during his tenure.
West Pharmaceutical Services reported fourth-quarter 2025 net sales of $805.0 million, up 7.5%, with reported diluted EPS of $1.82, up 2.2%, and adjusted diluted EPS of $2.04, up 12.1%. The company also issued 2026 guidance calling for adjusted diluted EPS of $7.85 to $8.20, which the filing says represents growth of 7.7% to 12.5%, and assumes a mid-year 2026 close of the SmartDose 3.5mL sale to AbbVie.
Q4 2025 net sales of $805.0 million rose 7.5%; organic growth was 3.3%, with HVP Components up 20.3%.
Q4 2025 diluted EPS was $1.82 (up 2.2%); adjusted diluted EPS was $2.04 (up 12.1%).
2026 guidance: net sales of $3.215 billion to $3.275 billion and adjusted diluted EPS of $7.85 to $8.20.
Full-year 2025 free cash flow was $468.9 million, up 69.6%; 2025 share repurchases totaled $134.0 million.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every West Pharmaceutical Services filing is on SEC EDGAR ↗. 8-K briefs of other companies →